Imagine suddenly feeling your heart racing out of control, pounding at over 150 beats per minute, leaving you breathless, dizzy, and terrified—it's a nightmare for millions, and now, there's a game-changing solution on the horizon. But here's where it gets controversial: could empowering patients to treat themselves at home really be the best way forward, or does it open the door to unnecessary risks? In this exciting development, we're diving into Milestone Pharmaceuticals' FDA approval of CARDAMYST™ (etripamil), the first and only self-administered nasal spray designed for adults battling paroxysmal supraventricular tachycardia (PSVT). And this is the part most people miss—how this innovation not only transforms treatment but also sparks debates about patient autonomy in heart health management. Let's break it down step by step, making complex medical concepts accessible even for beginners, so you can understand the full impact.
For over two million Americans living with PSVT—a condition where the heart's rhythm goes haywire in unpredictable bursts—this approval marks the first new FDA-endorsed treatment option in more than 30 years. PSVT, often called SVT for short, involves sudden episodes of abnormally fast heartbeats, typically lasting hours and causing intense symptoms like pounding palpitations, shortness of breath, chest pain, or dizziness. These flare-ups can force people to rush to the emergency room, disrupting their lives and racking up costly visits. Until now, effective relief usually meant intravenous medications in a clinical setting, which added stress and inconvenience. CARDAMYST changes the game by offering a novel nasal spray that acts as a rapid calcium channel blocker, allowing users to self-administer it right when symptoms strike, potentially restoring normal sinus rhythm quickly and giving patients a sense of control wherever they are.
But here's the twist—while empowering individuals sounds revolutionary, some experts might argue it's risky, especially for those without medical supervision. Could self-treatment lead to misuse or overlooked complications? We'll explore that angle later. The FDA's green light paves the way for CARDAMYST to hit retail pharmacies in early 2026, building on Milestone's solid financial footing from existing funds and royalty agreements.
Delving deeper, CARDAMYST isn't just another medication; it's engineered for on-demand use during PSVT episodes, which are often highly symptomatic and erratic. Picture this: instead of waiting helplessly or rushing to a hospital, adults with PSVT can carry this spray like an EpiPen, ready to deploy at a moment's notice. This approach empowers proactive management, reducing the anxiety of anticipating the next attack.
Joseph Oliveto, President and CEO of Milestone Pharmaceuticals, captured the excitement perfectly: 'CARDAMYST represents a groundbreaking, always-at-the-ready option that tackles the erratic nature of PSVT by letting patients handle episodes on their own terms, anytime and anywhere.' He went on to express deep gratitude to the team, patients, investigators, and healthcare providers who made this milestone possible.
James Ip, M.D., a leading etripamil researcher, echoed the human side: 'Many PSVT sufferers have lived with constant worry, dreading the next episode and the hassle of ER trips. CARDAMYST empowers them to self-treat quickly, potentially sidestepping hospital visits altogether.'
Backing this up is a comprehensive body of clinical evidence from over 1,800 participants and 2,000 PSVT episodes. The standout is the Phase 3 RAPID trial, a global, randomized, double-blind study pitting CARDAMYST against a placebo, with results published in The Lancet in 2023. Users of CARDAMYST were twice as likely to revert to normal heart rhythm and did so over three times faster than those on placebo. Specifically, 64% of the 99 participants using the spray achieved conversion within 30 minutes, compared to just 31% of the 85 on placebo—a statistically significant win. By the one-hour mark, 73% had success. Moreover, the median time to conversion was a swift 17 minutes for CARDAMYST versus 54 minutes for placebo, with benefits kicking in early and lasting.
Safety data shines across demographics, including those already taking beta blockers or other calcium channel blockers. Common side effects, mostly mild and temporary, affected at least 5% of users in trials: nasal discomfort, congestion, runny nose, throat irritation, and nosebleeds. Fewer than 2% dropped out due to adverse reactions.
For detailed safety info, check the Important Safety Information below or visit Milestone's site. PSVT patients can learn more at SVTHearttoHeart.com.
Lorenz Muller, Milestone's Chief Commercial Officer, emphasized their mission: 'We aim for CARDAMYST to become a go-to tool for doctors and their patients, and we're hustling to get it into pharmacies fast, securing insurance and distribution.' Annette Greene, a trial participant and admin of a large SVT Facebook group, added, 'PSVT patients have longed for this self-empowerment—now it's here!'
Looking ahead, Milestone is gearing up for Phase 3 trials in atrial fibrillation with rapid ventricular rate (AFib-RVR), leveraging the successful ReVeRA Phase 2 trial published in Circulation: Arrhythmia and Electrophysiology. They'll use an sNDA pathway for a potential second use of etripamil, drawing on PSVT data plus a new pivotal study.
To clarify for newcomers: PSVT affects about two million U.S. adults with episodes of rapid heartbeats (150-200+ bpm) that can last hours, causing severe symptoms and limiting daily life. The unpredictability breeds anxiety, especially for those with other conditions like heart failure. Traditional treatments often involve costly ER visits or invasive procedures.
AFib-RVR impacts around ten million Americans with irregular, fast heartbeats, leading to palpitations and weakness. Many end up in ERs—nearly 800,000 in 2016—for IV meds or shocks. Milestone's research suggests 30-40% of AFib patients face treatable RVR episodes yearly, targeting a market of three to four million by 2030.
CARDAMYST is approved for converting acute PSVT episodes to sinus rhythm in adults.
IMPORTANT SAFETY INFORMATION FOR CARDAMYST (etripamil)
What is CARDAMYST?
It's a prescription nasal spray to restore normal heart rhythm in adults experiencing sudden fast-heartbeat episodes of PSVT.
It's not tested for safety or effectiveness in kids.
Don't use CARDAMYST if:
- You're allergic to it or its ingredients (see full list in Patient Information).
- You have moderate to severe heart failure limiting activities.
- You have Wolff-Parkinson-White syndrome, Lown-Ganong-Levine syndrome, or pre-excitation on an ECG.
- You have sick sinus syndrome without a pacemaker.
- You have second-degree or higher AV block.
Before using, tell your doctor about:
- Fainting history.
- Low blood pressure.
- Pregnancy or plans to conceive (unknown effects on unborn baby).
- Breastfeeding (unknown if it passes into milk; stop nursing for 12 hours, pump and discard milk).
Also, disclose all meds, including OTC, vitamins, and supplements.
Possible side effects:
Serious ones include fainting from effects on blood pressure, heart rate, or rhythm—especially risky for those with fainting history or certain heart issues. Use sitting in a safe spot; lie down if dizzy. Seek help if fainting occurs.
Common side effects:
- Nasal discomfort
- Congestion
- Runny nose
- Throat irritation
- Nosebleed
These aren't all possible effects. Report to FDA at 1-800-FDA-1088. Full Prescribing Info at Milestone's site.
Milestone is financially ready to launch CARDAMYST, with $82.6 million in cash and equivalents as of September 30, 2025, plus a $75 million royalty deal with RTW Investments (amended to extend approval deadline to December 31, 2025). Today's FDA nod should trigger that payout.
Join the conference call and webcast on December 15, 2025, at 8:00 a.m. ET for more details. Dial in or access online via Milestone's site.
About Milestone: They're a biopharma focused on heart meds, with CARDAMYST as their flagship nasal spray for PSVT, and etripamil advancing for AFib-RVR.
Forward-Looking Statements: This includes projections like product availability timing and trial outcomes, based on current assumptions. Actual results may vary due to risks like FDA interactions, trial complexities, or economic factors. See SEC filings for details.
Contacts: Investor Relations - Kevin Gardner; Media - Rebecca Novak.
And this is the part most people miss—the potential controversy around self-medication. While it offers freedom, does it encourage over-reliance without professional checks? What if patients misjudge symptoms or delay real care? Do you think this empowers patients or shifts too much responsibility? Share your thoughts in the comments—do you agree with this approach, or do you see pitfalls? Let's discuss!
